This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

6 Aug 2012

Gilead to Collaborate with Indian Partners on Generic Versions of Emtricitabine

Gilead and its partners in India aim to improve access to affordable antiretroviral therapy for HIV patients in developing countries.

Gilead Sciences has entered into agreements with generic partners in India to produce low-cost versions of its HIV medicine emtricitabine (FTC).


The antiretroviral therapy is recommended by the World Health Organisation as a component of both first and second-line treatment for HIV infection, but cost is a barrier to access in developing countries.


Under the new agreements with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, Gilead will provide a technology transfer for the manufacture of high volumes of emtricitabine.


The biopharmaceutical company will also provide funding to improve manufacturing processes

Related News